Akademik Veri Yönetim Sistemi
Electrochimica Acta, cilt.540, 2025 (SCI-Expanded, Scopus)
Pomalidomide (POM) is a potent second-generation immunomodulatory drug with proven efficacy in treating multiple myeloma and promising therapeutic potential in myelofibrosis due to its ability to enhance erythropoietic function with a favorable toxicity profile. In this work, we report for the first time the development of a holmium oxide/zirconium-modified glassy carbon electrode (Ho₂O₃/Zr/GCE) as a highly sensitive and selective electrochemical sensor for the determination of POM in pharmaceutical formulations and biological fluids. The Ho₂O₃/Zr nanocomposite was synthesized and thoroughly characterized by Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX), confirming its successful formation with desirable structural and morphological features. Electrochemical measurements were carried out in Britton–Robinson (BR) buffer (pH 5.0) using differential pulse voltammetry (DPV) under optimized conditions. The sensor exhibited an excellent linear response over the range of 0.15–3.3 μM (R² = 0.999) with an exceptionally low detection limit (LOD) of 1.8 nM and a quantification limit (LOQ) of 6.0 nM. The Ho₂O₃/Zr/GCE displayed outstanding repeatability, reproducibility, and selectivity against common interfering species. Its applicability was successfully demonstrated in human serum, urine, and pharmaceutical capsule samples, yielding high recoveries (97.54–101.2 %) and low relative standard deviation (RSD) values (0.7–3.2 %). These results highlight the novelty and analytical potential of the Ho₂O₃/Zr/GCE platform as a cost-effective, high-performance tool for routine POM detection in complex real-world matrices.